BioLineRx (NASDAQ:BLRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of BioLineRx (NASDAQ:BLRX) in a research note issued to investors on Saturday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Several other research firms have also issued reports on BLRX. Jones Trading restated a “hold” rating on shares of BioLineRx in a report on Wednesday, April 2nd. HC Wainwright upped their target price on BioLineRx from $9.00 to $26.00 and gave the company a “buy” rating in a research report on Monday, March 31st.

BioLineRx Price Performance

BioLineRx stock opened at $3.17 on Friday. The stock’s 50 day moving average is $3.06 and its 200 day moving average is $6.94. BioLineRx has a one year low of $2.30 and a one year high of $35.60. The firm has a market cap of $10.55 million, a P/E ratio of -0.36 and a beta of 1.15. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.52 and a quick ratio of 1.37.

Hedge Funds Weigh In On BioLineRx

A hedge fund recently bought a new stake in BioLineRx stock. Highbridge Capital Management LLC purchased a new position in BioLineRx Ltd. (NASDAQ:BLRX) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned approximately 50.50% of BioLineRx as of its most recent filing with the Securities and Exchange Commission (SEC). 1.56% of the stock is currently owned by hedge funds and other institutional investors.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.